In 5 of 68 (7%) of tumor samples, novel whole-exome sequencing data identified alterations in the fibroblast growth factor receptor 4 (FGFR4) as a potential therapeutic target based on high expression, recurrent amplification, and recurrent activating mutations [27]. Here, FGFR4 is linked to neoplasm.